Intracellular activity of antibiotics in a model of human THP-1 macrophages infected by a Staphylococcus aureus small-colony variant strain isolated from a cystic fibrosis patient: Study of antibiotic combinations

Antimicrobial Agents and Chemotherapy

Volumn 53, Issue 4, 2009, Pages 1443-1449

  Anh Nguyen, Hoang ^a   Denis, Olivier ^b   Vergison, Anne ^c   Tulkens, Paul M ^a   Struelens, Marc J ^b   Van Bambeke, Françoise ^a  

^a UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^b ERASME HOSPITAL   (Belgium)

^c UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

CLINDAMYCIN; DALFOPRISTIN PLUS QUINUPRISTIN; DAPTOMYCIN; FUSIDIC ACID; GENTAMICIN; LINEZOLID; MOXIFLOXACIN; ORITAVANCIN; OXACILLIN; RIFAMPICIN; VANCOMYCIN;

ANTIBACTERIAL ACTIVITY; ARTICLE; BACTERIAL STRAIN; BACTERIOSTASIS; COLONY FORMING UNIT; CONCENTRATION RESPONSE; CYSTIC FIBROSIS; DRUG EFFECT; DRUG POTENTIATION; HUMAN; HUMAN CELL; MACROPHAGE; MAXIMUM PLASMA CONCENTRATION; MOLECULAR MODEL; PRIORITY JOURNAL; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION;

ANTI-BACTERIAL AGENTS; CELL LINE; CYSTIC FIBROSIS; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; HUMANS; MACROPHAGES; STAPHYLOCOCCUS AUREUS;

EID: 65649085276     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01146-08     Document Type: Article

References (32)

1. Ãmsden, G. W. 2000. Tables of antimicrobial agents pharmacology, p. 635-700. In G. L. Mandeli, J. E. Bennett, and R. Dolin (ed.), Principles and practice of infectious diseases. Churchill Livingstone, New York, NY.
2. Baltch, A. L., W. J. Ritz, L. H. Bopp, P. Michelsen, and R. P. Smith. 2008. Activities of daptomycin and comparative antimicrobials, singly and in com-bination, against extracellular and intracellular Staphylococcus aureus and its stable small-colony variant in human monocyte-derived macrophages and in broth. Antimicrob. Agents Chemother. 52:1829-1833.
3. Baltch, A. L., W. J. Ritz, L. H. Bopp, P. B. Michelsen, and R. P. Smith. 2007. Antimicrobial activities of daptomycin, vancomycin, and oxacillin in human monocytes and of daptomycin in combination with gentamicin and/or ri-fampin in human monocytes and in broth against Staphylococcus aureus. Antimicrob. Agents Chemother. 51:1559-1562. (Pubitemid 46586853)
4. Bamberger, D. M., B. L. Herndon, M. Dew, R. P. Chern, H. Mitchell, L. E. Summers, R. F. Marcus, S. C. Kim, and P. R. Suvarna. 1997. Efficacies of ofloxacin, rifampin, and clindamycin in treatment of Staphylococcus aureus abscesses and correlation with results of an in vitro assay of intracellular bacterial killing. Antimicrob. Agents Chemother. 41:1178-1181. (Pubitemid 27194212)
5. Barcia-Macay, M., C. Serai, M. P. Mingeot-Leclercq, P. M. Tulkens, and F. Van Bambeke. 2006. Pharmacodynamic evaluation of the intracellular activ-ities of antibiotics against Staphylococcus aureus in a model of THP-I macrophages. Antimicrob. Agents Chemother. 50:841-851. (Pubitemid 43327786)
6. Belley, A., E. Neesham-Grenon, F. F. Arhin, G. A. McKay, T. R. Parr, Jr., and G. Moeck. 2008. Assessment of the synergistic effects of oritavancin tested in combination with other antimicrobial agents against Staphylococcus aureus by time-kill methodology. Antimicrob. Agents Chemother. 52:3820-3822.
7. Belley, A., E. Neesham-Grenon, S. Beaulieu, G. McKay, F. Arhin, T. R. Parr, Jr., and G. Moeck. 2007. Synergistic effects of oritavancin tested in combi-nation with other agents, abstr. E-1619. Abstr. 48th Intersci. Conf. Antimicrob. Agents Chemother. American Society for Microbiology, Washington, DC.
8. Besier, S., J. Zander, B. C. Kahl, P. Kraiczy, V. Brade, and T. A. Wichelhaus. 2008. The thymidine-dependent small-colony-variant phenotype is associ-ated with hypermutability and antibiotic resistance in clinical Staphylococcus aureus isolates. Antimicrob. Agents Chemother. 52:2183-2189.
9. Crandon, J., and D. P. Nicolau. 2008. Oritavancin: a potential weapon in the battle against serious gram-positive pathogens. Future Microbiol. 3:251-263.
10. Desbiolles, N., L. Piroth, C. Lequeu, C. Neuwirth, H. Portier, and P. Cha-vanet. 2001. Fractional maximal effect method for in vitro synergy between amoxicillin and ceftriaxone and between vancomycin and ceftriaxone against Enterococcus faecalis and penicillin-resistant Streptococcus pneumoniae. An-timicrob. Agents Chemother. 45:3328-3333. (Pubitemid 33107842)
11. Domenech, O., F. Van Bambeke, P. M. Tulkens, and M. P. Mingeot-Leclercq. 2008. Comparative study of membrane permabilization induced by oritavancin versus vancomycin in liposomes: importance of the acidic char-acter of the membrane, abstr.Cl-199. Abstr. 48th Intersci. Confer. Antimi-crob. Agents Chemother. (ICAAC)-Infect. Dis. Soc. Am. (IDSA) 46th Annu. Meet. American Society for Microbiology and Infectious Diseases Society of America, Washington, DC.
12. Eliopoulos, G. M., and C. T. Eliopoulos. 1988. Antibiotic combinations: should they be tested? Clin. Microbiol. Rev. 1:139-156. (Pubitemid 18259278)
13. Griffith, M. E., and H. L. Bodily. 1992. Stability of antimycobacterial drugs in susceptibility testing. Antimicrob. Agents Chemother. 36:2398-2402.
14. Lemaire, S., A. Olivier, F. Van Bambeke, P. M. Tulkens, P. C. Appelbaum, and Y. Glupczynski. 2008. Restoration of susceptibility of intracellular me-thicillin-resistant Staphylococcus aureus to ß-lactams: comparison of strains, cells, and antibiotics. Antimicrob. Agents Chemother. 52:2797-2805.
15. Lemaire, S., F. Van Bambeke, M. P. Mingeot-Leclercq, and P. M. Tulkens. 2005. Activity of three ß-lactams (ertapenem, meropenem and ampicillin) against intraphagocytic Listeria monocytogenes and Staphylococcus aureus. J. Antimicrob. Chemother. 55:897-904. (Pubitemid 40883174)
16. Li, R. C, J. J. Schentag, and D. E. Nix. 1993. The fractional maximal effect method: a new way to characterize the effect of antibiotic combinations and other nonlinear pharmacodynamic interactions. Antimicrob. Agents Chemother. 37:523-531. (Pubitemid 23072598)
17. McKay, G. A., I. Fadhil, S. Beaulieu, S. Ciblât, A. R. Far, G. Moeck, and T. R. Parr, Jr. 2006. Oritavancin disrupts transmembrane potential and membrane integrity concomitantly with cell killing in Staphylococcus aureus and vancomycin-resistant enterococci, abstr. Cl-682. Abstr. 46th Intersci. Conf. Antimicrob. Agents Chemother. American Society for Microbiology, Washington, DC.
18. Mercier, R. C, H. H. Houlihan, and M. J. Rybak. 1997. Pharmacodynamic evaluation of a new glycopeptide, LY333328, and in vitro activity against Staphylococcus aureus and Enterococcus faecium. Antimicrob. Agents Chemother. 41:1307-1312. (Pubitemid 27231432)
19. Mercier, R. C, C. Stumpo, and M. J. Rybak. 2002. Effect of growth phase and pH on the in vitro activity of a new glycopeptide, oritavancin (LY333328), against Staphylococcus aureus and Enterococcus faecium. J. Antimicrob. Chemother. 50:19-24.
20. Murillo, O., A. Domenech, A. Garcia, F. Tubau, C. Cabellos, F. Gudiol, and J. Ariza. 2006. Efficacy of high doses of Levofloxacin in experimental foreign-body infection by methicillin-susceptible Staphylococcus aureus. Antimicrob. Agents Chemother. 50:4011-4017.
21. Nguyen, H. A., O. Denis, A. Vergison, A. Theunis, P. M. Tulkens, M. J. Struelens, and F. Van Bambeke. 2009. Intracellular activity of antibiotics in a model of human THP-I macrophages infected by a Staphylococcus aureus small-colony variant strain isolated from a cystic fibrosis patient: pharmaco-dynamic evaluation and comparison with isogenic normal-phenotype and revertant strains. Antimicrob. Agents Chemother. 53:1434-1442.
22. Patel, R., M. S. Rouse, K, E. Piper, F. R. Cockerill III, and J. M. Steckelberg. 1998. In vitro activity of LY333328 against vancomycin-resistant enterococci, methicillin-resistant Staphylococcus aureus, and penicillin-resistant Strepto-coccus pneumoniae. Diagn. Microbiol. Infect. Dis. 30:89-92. (Pubitemid 28102862)
23. Patel, S. M., and L. D. Saravolatz. 2006. Monotherapy versus combination therapy. Med. Clin. N. Am. 90:1183-1195.
24. Perlroth, J., M. Kuo, J. Tan, A. S. Bayer, and L. G. Miller. 2008. Adjunctive use of rifampin for the treatment of Staphylococcus aureus infections: a systematic review of the literature. Arch. Intern. Med. 168:805-819. (Pubitemid 350166741)
25. Rowe, P. A., and T. J. Brown. 2001. Protein binding of 14C-oritavancin. Abstr. 41th Intersci. Conf. Antimicrob. Agents Chemother., abstr. A-2193.
26. Schwalbe, R. S., A. C. McIntosh, S. Qaiyumi, J. A. Johnson, R. J. Johnson, K. M. Furness, W. J. Holloway, and L. Steele-Moore. 1996. In vitro activity of LY333328, an investigational glycopeptide antibiotic, against enterococci and staphylococci. Antimicrob. Agents Chemother. 40:2416-2419. (Pubitemid 26328057)
27. Van Bambeke, F., M. Barcia-Macay, S. Lemaire, and P. M. Tulkens. 2006. Cellular pharmacodynamics and pharmacokinetics of antibiotics: current views and perspectives. Curr. Opin. Drag Discov. Devel. 9:218-230.
28. Van Bambeke, F., S. Carryn, C. Serai, H. Chanteux, D. Tyteca, M. P. Mingeot-Leclercq, and P. M. Tulkens. 2004. Cellular pharmacokinetics and pharmacodynamics of the glycopeptide antibiotic oritavancin (LY333328) in a model of J774 mouse macrophages. Antimicrob. Agents Chemother. 48: 2853-2860. (Pubitemid 38989146)
29. Van Bambeke, F., Y. Van Laethem, P. Courvalin, and P. M. Tulkens. 2004. Glycopeptide antibiotics: from conventional molecules to new derivatives. Drugs 64:913-936. (Pubitemid 38608472)
30. von Eiff, C. 2008. Staphylococcus aureus small colony variants: a challenge to microbiologists and clinicians. Int. J. Antimicrob. Agents 31:507-510.
31. von Eiff, C, G. Peters, and K. Becker. 2006. The small colony variant (SCV) concept: the role of staphylococcal SCVs in persistent infections. Injury 37(Suppl. 2):S26-S33.
32. Zhanel, G. G., I. D. Kirkpatrick, D. J. Hoban, A. M. Kabani, and J. A. Karlowsky. 1998. Influence of human serum on pharmacodynamic proper-ties of an investigational glycopeptide, LY333328, and comparator agents against Staphylococcus aureus. Antimicrob. Agents Chemother. 42:2427-2430. (Pubitemid 28420391)